## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($335.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cencora Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T214300 | Neutral | Relevance: 99%
- Cencora Inc. (COR) stock declined by 2.39% on Monday, closing at $360.12, performing worse than the overall market. The S&P 500 Index and Dow Jones Industrial Average also saw declines on the same day. Cencora Inc. ended the trading session 4.61% below its 52-week high.

**2. Cencora (COR) Upgraded to Buy: Here's Why**
- Source: www.sharewise.com | 20251202T213645 | Bullish | Relevance: 98%
- Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy) primarily due to an upward trend in earnings estimates, which is a strong indicator of future stock price movements. The Zacks rating system emphasizes the power of changing earnings pictures and estimate revisions, which have historically correlated with near-term stock price changes. This upgrade suggests an improvement in Cencora's underlying business and positions it among the top 20% of Zacks-covered stocks based on estimate revisions.

**3. Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus**
- Source: TradingView | 20251201T160628 | Somewhat-Bullish | Relevance: 73%
- This article highlights how Zacks Investment Research methodologies have successfully guided investors, showcasing various stock picks and portfolios that have outperformed the market. It details specific stock achievements from Zacks Rank upgrades, Zacks Recommendation upgrades, Focus List, ECAP, ECDP, and Top 10 Stocks categories, demonstrating significant returns against S&P 500 performance. The piece emphasizes Zacks' approach to provide unbiased guidance and forecasts despite prevailing market uncertainty, such as the Federal Reserve's potential interest rate cuts.

**4. What Recent Specialty Pharma Moves Mean for Cardinal Healthâ€™s Stock Valuation**
- Source: Simply Wall Street | 20251202T193655 | Neutral | Relevance: 64%
- This article analyzes Cardinal Health's (NYSE:CAH) stock valuation following its expansion into specialty pharmaceuticals. The company's stock has seen significant growth, with a 76.2% year-to-date increase. Using discounted cash flow (DCF) analysis, Simply Wall St suggests Cardinal Health is undervalued by 55.0%, while its P/E ratio indicates it is "about right" given its financial profile and potential.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (2 raises, avg +18%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.1B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 17.9 |
| Current P/E | 19.8 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.2% to -6.2% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.2pp (needs >3.0% for momentum thesis). Underperforming sector by 5.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-2.66), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.15% (CS: 2) | Weak |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | -2.66 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.180x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $350.67
- **Stop Loss:** $335.39 (4.4% risk)
- **Target:** $365.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $22,793.55
- **Portfolio %:** 22.79%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*